Cargando…
Boehringer Ingelheim and Eli Lilly and Company announces trategic alliance to bring new diabetes treatments to patients worldwide
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Clinics Cardive Publishing
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053646/ https://www.ncbi.nlm.nih.gov/pubmed/21298208 |
Ejemplares similares
-
VI Scandinavian COPD Research Symposium Published with support from Boehringer Ingelheim
Publicado: (2015) -
Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)
Publicado: (2010) -
The Epidemiological Boehringer Ingelheim Employee Study—Part I: Impact of Overweight and Obesity on Cardiometabolic Risk
por: Kempf, Kerstin, et al.
Publicado: (2013) -
Were Eli Lilly Unaware of This Study?
por: Reidak, Aasa
Publicado: (2006) -
The Epidemiological Boehringer Ingelheim Employee Study (Part 3): Association of Elevated Fasting Insulin Levels but Not HOMA-IR With Increased Intima Media Thickness and Arteriosclerosis in Middle-Aged Persons
por: Röhling, Martin, et al.
Publicado: (2021)